{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-000648","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.280994+00:00","generated_at":"2026-06-06T06:23:46.701549+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Cassava Sciences: simufilam shows stable ADAS-Cog in mild Alzheimer's over 24 months","bullets":["Mild Alzheimer's patients on continuous simufilam (n=47) averaged 0.07 point ADAS-Cog change (±1.51 SE) from baseline to month 24.","Non-continuous mild group (n=40) declined 1.04 points on ADAS-Cog (±1.65 SE); largest separation during placebo withdrawal.","Moderate Alzheimer's patients on continuous simufilam (n=32) declined 11.05 points on ADAS-Cog (±1.91 SE).","Simufilam 100 mg twice daily safe and well tolerated; no drug-related serious adverse events; common TEAEs were COVID-19 and UTI.","Phase 3 top-line results expected: 52-week study year-end 2024; 76-week study mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-000648","json":"https://secwatch.observer/filing/0001171843-24-000648.json","markdown":"https://secwatch.observer/filing/0001171843-24-000648.md","text":"https://secwatch.observer/filing/0001171843-24-000648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324000648/0001171843-24-000648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324000648/f8k_020724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T06:23:46.701549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}